Low RBC counts predict high on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention and treated with clopidogrel  

作　　者：Qian Gu Qin Wang Rui Hua Wenhao Zhang Jianzhen Teng Jiazheng Ma Zhou Dong Xiaoxuan Gong Chunjian Li 

机构地区：[1]Department of Cardiology,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China

出　　处：《The Journal of Biomedical Research》2024年第1期87-91,共5页生物医学研究杂志（英文版）

基　　金：supported by the National Natural Science Foundation of China(Grant No.82170351);the Jiangsu Province's Key Provincial Talents Program(Grant No.ZDRCA2016013);the Special Fund for Key R&D Plans(Social Development)of Jiangsu Province(Grant No.BE2019754).

摘　　要：Dear Editor,Cardiovascular disease is the leading cause of deaths worldwide,with coronary artery disease(CAD)accounting for approximately 50%of its mortality.Dual antiplatelet therapy,including aspirin and a P2Y12 inhibitor,is the most important treatment for CAD patients undergoing percutaneous coronary intervention(PCI)to prevent recurrent ischemic events and cardiac death.Clopidogrel is one of the commonly used P2Y12 inhibitors.However,up to 30%of patients treated with a standard dose of clopidogrel present with high on-treatment platelet reactivity(HOPR),which is associated with the increased ischemic risks[1].The causes of HOPR are multifactorial and complex.

关 键 词：CORONARY PATIENTS mortality 

分 类 号：R541.4[医药卫生—心血管疾病]